The document “Appendix 3Y Change of Director’s Interest Notice” was lodged with ASX on 22 November, 2021.
Please click to review the full announcement at ASX.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)